AN DER GOLDGRUBE 12, MAINZ, 2M
Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
Invitation to the 2026 Annual General Meeting
Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as Advances Toward Becoming a Multi-Product Company by 2030
Material disclosure
Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Translating Science into Survival
Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Tender Offer Statement by Third Party
No filings found
Amended Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Tender Offer Statement by Third Party
Amended Notice of Proposed Sale of Securities
S-8 POS